OncoMatch/Clinical Trials/NCT05379985
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Is NCT05379985 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies RMC-6236 for non-small cell lung cancer (nsclc).
Treatment: RMC-6236 — Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Pancreatic Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS G12 mutation
specific KRAS G12 mutations (dose escalation)
Required: KRAS mutation
RAS mutations (dose optimization/expansion)
Required: NRAS mutation
RAS mutations (dose optimization/expansion)
Required: HRAS mutation
RAS mutations (dose optimization/expansion)
Required: KRAS wild-type
PDAC with wild-type RAS (expansion)
Required: NRAS wild-type
PDAC with wild-type RAS (expansion)
Required: HRAS wild-type
PDAC with wild-type RAS (expansion)
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC Irvine/Chao Family Comprehensive Cancer Center · Orange, California
- UCLA · Santa Monica, California
- Moffitt Cancer Center · Tampa, Florida
- Johns Hopkins University · Baltimore, Maryland
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05379985 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require KRAS?
Yes, KRAS G12 mutation is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS mutation is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify